Compare ACDC & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACDC | OLMA |
|---|---|---|
| Founded | 2014 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 994.9M |
| IPO Year | 2021 | 2020 |
| Metric | ACDC | OLMA |
|---|---|---|
| Price | $4.88 | $12.06 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | $5.50 | ★ $44.89 |
| AVG Volume (30 Days) | 1.4M | ★ 1.9M |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 15.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,941,800,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.50 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.08 | $4.37 |
| 52 Week High | $8.43 | $36.26 |
| Indicator | ACDC | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 38.29 | 52.38 |
| Support Level | $4.73 | $7.79 |
| Resistance Level | $5.69 | $13.09 |
| Average True Range (ATR) | 0.37 | 0.69 |
| MACD | -0.00 | 0.10 |
| Stochastic Oscillator | 20.56 | 46.77 |
ProFrac Holding Corp is a technology-focused, vertically integrated energy services company providing hydraulic fracturing, proppant production, completion services, and related products, including distributed power generation, to upstream oil and natural gas companies in the United States. The Company operates through four segments: Stimulation Services, Proppant Production, Manufacturing, and Flotek. The Stimulation Services segment, which generates maximum revenue, provides hydraulic fracturing services using mobile units and auxiliary equipment. The Proppant Production segment supplies proppant, the Manufacturing segment sells engineered products such as pumps, valves, and piping, and Flotek is a chemistry and data technology company serving the E&P industry.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.